RADIESSE Injectable Implant
Merz North America, Inc. · Decision date Mar 18, 2026
What did the FDA decide?
FDA records P050037/S150 as a supplement to PMA P050037, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 18, 2026.
FDA approval order statement
the implementation of a new, alternate, GMP Equipment Washer to increase mixing components washing capacity
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Mar 18, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P050037/S150
- Regulatory pathway
- PMA supplement
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- Decision code
- OK30
- Decision date
- Mar 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P050037/S148 · Related supplement
RADIESSE 1.3CC AND 0.3CC
P050037/S149 · Related supplement
RADIESSE Injectable Implant
P050037/S150 received
Application receipt date recorded by FDA.
P050037/S150 · FDA decision
30-Day Notice
P050037/S151 · Related supplement
RADIESSE Injectable Implant
P050037/S152 · Related supplement
RADIESSE Injectable Implant
P050037/S153 · Related supplement
RADIESSE Injectable Implant
P050037/S154 · Related supplement
RADIESSE Injectable Implant
Timeline entries are records held by MedtechLedger for P050037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RADIESSE 1.3CC AND 0.3CCP050037/S148 | Merz North America, Inc. | PMA supplement | Dec 12, 2025 | FDA |
RADIESSE Injectable ImplantP050037/S149 | Merz North America, Inc. | PMA supplement | Jan 13, 2026 | FDA |
RADIESSE Injectable ImplantP050037/S151 | Merz North America, Inc. | PMA supplement | Mar 24, 2026 | FDA |
RADIESSE Injectable ImplantP050037/S152 | Merz North America, Inc. | PMA supplement | Mar 24, 2026 | FDA |
RADIESSE Injectable ImplantP050037/S153 | Merz North America, Inc. | PMA supplement | May 14, 2026 | FDA |
RADIESSE Injectable ImplantP050037/S154 | Merz North America, Inc. | PMA supplement | Jun 26, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merz North America, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4133 Ct.ney Rd., Suite 10, Franksville, WI, 53126
Sources and methodology
- Original FDA record: P050037/S150
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




